Mode
Text Size
Log in / Sign up

Case report details multimodal treatment for aggressive thyroid carcinoma

Case report details multimodal treatment for aggressive thyroid carcinoma
Photo by Alexander Grey / Unsplash
Key Takeaway
Multimodal therapy including surgery, radiotherapy, and systemic agents can stabilize aggressive thyroid carcinoma with pulmonary metastases.

This case report details the management of a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma, which later presented as differentiated high-grade disease with pulmonary metastases. The patient underwent a thyroidectomy and neck dissection as the primary surgical intervention. Following surgery, adjuvant radiotherapy was administered to address local disease control.

The treatment plan was further intensified with the addition of targeted therapy and immunotherapy, reflecting a multimodal approach for this aggressive presentation. The patient's course was monitored within six months of the initial diagnosis, with the primary goal of achieving disease stabilization.

The main outcome reported was disease stabilization, which was successfully achieved through this comprehensive therapeutic strategy. This result underscores the potential utility of combining surgical, radiation, and systemic therapies for advanced thyroid carcinoma cases. The report does not specify long-term outcomes or comparative effectiveness against other regimens.

Limitations include the single-patient design and lack of a comparator group, which restrict generalizability. The report also does not detail specific agents used, safety profiles, or funding sources. Despite these constraints, the case provides a practical example of integrating multiple treatment modalities for a complex thyroid cancer presentation.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Differentiated high-grade thyroid carcinoma (DHGTC) is relatively uncommon. This case report described a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma confined to the thyroid gland, accompanied by skip metastasis to a Level II lymph node. The metastatic lymph node exhibited histopathological progression to DHGTC. Following thyroidectomy for the primary tumor and neck dissection for the metastatic lymph node, the patient received adjuvant radiotherapy to the neck. Subsequently, pathological examination confirmed multiple pulmonary metastases (PMs) from DHGTC within six months of the initial diagnosis. Unfortunately, a post-therapeutic ¹³¹I scan revealed no uptake in the PMs. Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient’s condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.